Genes and Diabetes Increase Heart Problems Ivanhoe, FL - Now researchers believe patients with type 2 diabetes along with a genetic variation have an increased risk for coronary artery disease (CAD). ...
Chromosome linked to diabetics' heart risks Tehran Times, Iran - Nov 29, 2008 Compared to patients with good glycemic control and no 9p21 gene risk variant, those subjects with two risk gene variants and good glycemic control were ...
Gene Variation Leads to Increased Risk of CAD in Diabetes Patients Genetic Engineering News (press release), NY - Nov 26, 2008 Genetic variation on chromosome 9p21 has been associated with increased risk of coronary artery disease (CAD) in the general population. ...
Scientists doubt utility of CT scan as heart test Reuters - Nov 26, 2008 CT scanning, used to diagnose coronary artery blockages, is one case where the US government appears to be wasting money because pressures to pay for ...
Ways to relieve stress Los Angeles Times, CA - Nov 28, 2008 If you feel socially isolated and lack the emotional support of people around you, you're at an increased risk of mortality, illness and coronary disease. ...
The Genetic Privacy of Presidential Candidates New England Journal of Medicine (subscription), MA - Nov 19, 2008 For example, the risk of bipolar disorder is reportedly increased by a gene encoding diacylglycerol kinase eta (DGKH) and decreased by a particular allele ...
Recent News and Articles on the Keywords: 304,000 + web + 0.38 Related to the article below (Last Update: 8/7/2008)
Momentum Announces Q4 and Year End Results FOXBusiness - Jul 23, 2008 Web Solutions and Services ("WSS") revenue increased 21% to $3317372 vs. $2746000 - Net income from continuing operations was $242630 vs. a loss of $61000 ...TSE:WWW - OTC:CMTX
Altera Announces Second Quarter Results WELT ONLINE, Germany - Jul 15, 2008 The web cast and subsequent replay will be available in the investor relations section of the company's web site at http://www.altera.com. ...ALTR - COL
Medifast Announces Second Quarter 2008 Financial Results Earthtimes (press release), UK - The Company will hold a conference call and web cast to discuss the results on Thursday, August 7 , at 11:00 am ET . Interested parties can access the call ...MED
Wyndham Worldwide Reports Solid Second Quarter 2008 Results PR Newswire (press release), NY - Jul 31, 2008 Listeners may access the webcast live through the Company's Web site at http://www.wyndhamworldwide.com/investors/. An archive of this webcast will be ...WYN
Rigid market means no one can move This is Money, UK - Jul 25, 2008 'We had bought it in 2006 for ?304000 and were thrilled when we had two local estate agents - Gascoigne Pees and James Anderson - value it at ?479000 and ...
Big profit seen for Chevron despite loss from refining San Francisco Chronicle, USA - Jul 10, 2008 A year ago, the figure was lower, at 304000, showing a deterioration in employment conditions. A government analyst cautioned that last week's drop did not ...CVX
German July New Car Sales Up Around 1.5% - Source FXstreet.com The Foreign Exchange Market, Spain - Aug 4, 2008 In June 2007 new car sales in Germany rose 1% to 304000 cars from 257000 a year earlier. The Dow Jones content is the property of Dow Jones or its licensors ...
[PDF]Resource-constrained scheduling of tests in new product development - V Jain, IE Grossmann - Ind. Eng. Chem. Res, 1999 - cepac.cheme.cmu.edu ... 3013 Ind. Eng. Chem. Res. 1999, 38, 3013 - 3026 10.1021/ie9807809 CCC: $18.00 ?
1999 American Chemical Society Published on Web 07/02/1999 Page 2. ... -
Source: Google Scholar
Acute coronary syndrome, gene variants linked to increased risk of death in patients treated with beta-blockers
Patients with certain gene variants who were prescribed beta-blocker drugs after acute coronary syndrome ( ACS ) had an increased risk of death over the next three years.
Previous data support an association between variants of the ADRB1 and ADRB2 genes and response to beta-blocker therapy, but no relationship between these variants and the survival of patients receiving beta-blocker therapy has been reported.
David E. Lanfear, formerly of Washington University School of Medicine, St. Louis, and colleagues conducted a prospective cohort study of 735 acute coronary syndrome patients admitted to two medical centers between March 2001 and October 2002.
The ACS patients were diagnosed with either myocardial infarction or unstable angina.
Among those enrolled in the study, 597 were discharged from the hospital with beta-blocker therapy.
DNA testing was conducted to find out if the patients carried any of four common variants of the ADRB1 and ADRB2 genes ( ADRB1 1165 CG, 145 AG; ADRB2 46 GA, 79 CG ).
The researchers followed the study patients for three years after discharge. There were 84 deaths during follow-up.
" There was a significant association between ADRB2 genotype and three-year mortality among patients prescribed beta blocker therapy," the authors report.
" For the 79 CG polymorphism, … three-year mortality rates were 16 percent ( 35 deaths ), 11 percent ( 27 deaths ), and six percent ( four deaths ) for the CC, CG, and GG genotypes, respectively," they write. " For the ADRB2 46 GA polymorphism, three-year … mortality estimates were ten percent ( 17 deaths ), ten percent ( 28 deaths ), and 20 percent ( 20 deaths ) for the GG, GA, and AA genotypes, respectively."
No increased mortality risk was observed in patients with the same ADRB2 gene variants who were not prescribed beta-blockers. No association of the ADRB1 variants with mortality was observed in either the beta-blocker group, or in the patients who were not prescribed beta-blockers.
The researchers believe this initial description of an association of ADRB2 genotype with survival among patients receiving beta-blocker therapy has potentially important implications.
" Among acute coronary syndrome patients discharged with beta-blocker therapy, we have identified a genetic association with survival that can assist in the risk stratification of patients," they write. " Specifically, the 79 CC and 46 AA groups ( 39 percent and 16 percent, respectively, of our population ) are at high risk for long-term mortality and may need additional treatments to optimize their prognosis."
" We strongly encourage further replication of our findings in distinct patient cohorts so that the potential benefit or harm of beta-blocker therapy within specific ADRB2 genotype groups can be definitively demonstrated," the authors conclude. " With further validation, pharmacogenetic targeting of beta-blocker therapy may be an opportunity to further improve ACS care and outcomes."
